Global Stomach Cancer Treatment Market Insights Forecasts to 2033

• The Global Stomach Cancer Treatment Market Size was Valued at USD 4.77 Billion in 2023
• The Market Size is Growing at a CAGR of 12.47% from 2023 to 2033
• The Worldwide Stomach Cancer Treatment Market Size is Expected to Reach USD 15.45 Billion by 2033
• Middle East & Africa is Expected to Grow the fastest during the forecast period.

The Global Stomach Cancer Treatment Market Size is Anticipated to Exceed USD 15.45 Billion by 2033, Growing at a CAGR of 12.47% from 2023 to 2033.

Market Overview

One kind of cancer that starts in the lining of the stomach is called stomach cancer, sometimes referred to as gastric cancer. Radiation therapy, chemotherapy, immunotherapy, targeted therapy, and surgery (partial or total gastrectomy and lymphadenectomy) are available forms of treatment. Palliative treatment is also necessary for advanced symptom management. Abnormal cell growth that begins in the stomach is known as stomach cancer. Gastric cancer is the fifth most common cancer globally and one of the main causes of cancer-related deaths. Stomach cancer can be detected sooner due to advancements in molecular diagnostics, computed tomography (CT) scans, and endoscopic ultrasonography (EUS). Rising geriatric populations, sedentary lifestyles, and the significant impact of dietary changes are expected to drive the growth of the stomach cancer treatment market. Increased diagnosis rates, healthcare access, and lifestyle factors are all correlated, which makes market expansion in this industry even more urgent.    

Report Coverage

This research report categorizes the stomach cancer treatment market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the stomach cancer treatment market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the stomach cancer treatment market.

Driving Factors

Research and development (R&D) spending is crucial for fostering innovation in treating stomach cancer. The increasing global incidence of stomach cancer is a significant market driver, influenced by dietary changes, lifestyle modifications, and population aging. Government initiatives to increase cancer awareness, early detection programs, and funding for stomach cancer research and treatment development are major factors driving the growth of the stomach cancer treatment market.   

Restraining Factors

The market for stomach cancer treatment is restricted by factors such as high treatment costs, restricted access to cutting-edge therapies in underdeveloped nations, unfavourable side effects, a dearth of early detection techniques, and difficulties with drug approval regulations. 

Market Segmentation

The stomach cancer treatment market share is classified into treatment type, disease indication, and route of administration.   

• The targeted therapy segment is estimated to hold the largest market revenue share through the projected period.  

Based on the treatment type, the stomach cancer treatment market is classified into standard chemotherapy, targeted therapy, and immunotherapy. Among these, the targeted therapy segment is estimated to hold the largest market revenue share through the projected period. Targeted therapy allows for precise cancer cell targeting with the least damage to nearby healthy tissues. This particular method lessens related negative effects and increases therapeutic efficacy.

• The gastric cancer/gastroesophageal junction cancer segment is anticipated to hold the largest market share through the forecast period.

Based on disease indication, the stomach cancer treatment market is divided into gastric cancer/gastroesophageal junction cancer and gastrointestinal stromal tumors. Among these, the gastric cancer/gastroesophageal junction cancer segment is anticipated to hold the largest market share through the forecast period. Gastric cancer and gastric-esophageal junction cancer are driven by their high global incidence and corresponding death rates. 

• The injectable segment is anticipated to hold the largest market share through the forecast period.

Based on the route of administration, the stomach cancer treatment market is divided into oral and injectable. Among these, the injectable segment is anticipated to hold the largest market share through the forecast period. Rapid therapeutic action and efficacy in delivering chemotherapy and targeted medicines straight into the bloodstream are two advantages of injectable treatment.    

Regional Segment Analysis of the Stomach Cancer Treatment Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

Asia Pacific is anticipated to hold the largest share of the stomach cancer treatment market over the predicted timeframe.

Asia Pacific is anticipated to hold the largest share of the stomach cancer treatment market over the predicted timeframe. The Asia Pacific stomach cancer treatment market, such as China and Japan, has some of the highest rates of gastric cancer worldwide. The need for efficient treatment options is driven by rising awareness of stomach cancer and improvements in healthcare access, making this area a major focus for market expansion. With over 478,000 new cases reported each year, stomach cancer's alarming incidence rates serve as the nation's main factor driving the Asia Pacific region.   

Middle East & Africa is expected to grow at the fastest CAGR growth of the stomach cancer treatment market during the forecast period. The region is seeing an increase in demand for alternative treatments for stomach cancer as awareness of the disease grows and healthcare infrastructure advances. Incidence rates have increased due to an increase in lifestyle-related risk factors, which calls for efficient treatment options in this region.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the stomach cancer treatment market along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Samsung Bioepis
• Novartis AG
• Mylan N.V.
• F. Hoffmann-La Roche Ltd
• Eli Lilly and Company
• Merck & Co., Inc.
• CELLTRION INC.
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Bristol-Myers Squibb Company
• Others   

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

Recent Development

• In May 2024, In HER2-positive gastric or GEJ adenocarcinoma, Merck announced that the Phase 3 KEYNOTE-811 trial achieved its dual primary endpoint of overall survival for KEYTRUDA in combination with trastuzumab and chemotherapy.   

• In January 2024, Novartis announced that Lutathera dramatically decreased the risk of mortality or disease progression by 72% in advanced gastroenteropancreatic neuroendocrine tumours, demonstrating the efficacy of radioligand therapy as a first-line treatment. 

Market Segment

• This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the stomach cancer treatment market based on the below-mentioned segments: 

Global Stomach Cancer Treatment Market, By Treatment Type  

• Standard Chemotherapy
• Targeted Therapy
• Immunotherapy

Global Stomach Cancer Treatment Market, By Disease Indication   

• Gastric Cancer/Gastroesophageal Junction cancer
• Gastrointestinal Stromal Tumors

Global Stomach Cancer Treatment Market, By Route of Administration

• Oral
• Injectable

Global Stomach Cancer Treatment Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa